Table of Contents
ISRN Oncology
Volume 2012, Article ID 242850, 7 pages
http://dx.doi.org/10.5402/2012/242850
Clinical Study

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer

1Department of Oncology, Wayne State University and Karmanos Cancer Center, Detroit, MI 48201, USA
2Division of Hematology/Oncology, Henry Ford Health System, Detroit, MI 48202, USA
3Department of Medicine, Section of Oncology, John D. Dingell VA Medical Center, Detroit, MI 48201, USA

Received 18 March 2012; Accepted 9 April 2012

Academic Editors: S. Honoré and B. Luber

Copyright © 2012 Shin Ogita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Han, A. W. Partin, S. Piantadosi, J. I. Epstein, and P. C. Walsh, “Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer,” The Journal of Urology, vol. 166, no. 2, pp. 416–419, 2001. View at Google Scholar · View at Scopus
  2. A. A. Caire, L. Sun, O. Ode et al., “Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?” Urology, vol. 74, no. 3, pp. 643–647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. J. E. Sylvester, J. C. Blasko, P. D. Grimm, R. Meier, and J. A. Malmgren, “Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience,” International Journal of Radiation Oncology Biology Physics, vol. 57, no. 4, pp. 944–952, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. C. R. Pound, A. W. Partin, M. A. Eisenberger, D. W. Chan, J. D. Pearson, and P. C. Walsh, “Natural history of progression after PSA elevation following radical prostatectomy,” The Journal of the American Medical Association, vol. 281, no. 17, pp. 1591–1597, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. S. J. Freedland, E. B. Humphreys, L. A. Mangold et al., “Risk of prostate cancer—specific mortality following biochemical recurrence after radical prostatectomy,” The Journal of the American Medical Association, vol. 294, no. 4, pp. 433–439, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. “Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The medical research council prostate cancer working party investigators group,” British Journal of Urology, vol. 79, no. 2, pp. 235–246, 1997.
  7. M. R. Smith, F. Kabbinavar, F. Saad et al., “Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 13, pp. 2918–2925, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. R. Smith, R. Cook, K. A. Lee, and J. B. Nelson, “Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer,” Cancer, vol. 117, no. 10, pp. 2077–2085, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. M. R. Smith, F. Saad, R. Coleman et al., “Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial,” The Lancet, vol. 379, no. 9810, pp. 39–46, 2012. View at Publisher · View at Google Scholar
  10. L. G. Presta, H. Chen, S. J. O'Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. View at Google Scholar · View at Scopus
  11. G. di Lorenzo, W. D. Figg, S. D. Fossa et al., “Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study,” European Urology, vol. 54, no. 5, pp. 1089–1096, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Francini, A. Pascucci, E. Francini et al., “Bevacizumab and weekly docetaxel in patients with metastatic castrate-resistant prostate cancer previously exposed to docetaxel,” Prostate Cancer, vol. 2011, Article ID 258689, 7 pages, 2011. View at Publisher · View at Google Scholar
  13. R. W. Ross, M. D. Galsky, P. Febbo et al., “Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer,” Cancer. In press.
  14. G. J. Bubley, M. Carducci, W. Dahut et al., “Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the prostate—specific antigen working group,” Journal of Clinical Oncology, vol. 17, no. 11, pp. 3461–3467, 1999. View at Google Scholar · View at Scopus
  15. E. Lee and J. Wang, Statistical Methods for Survival Data Analysis, John Wiley & Sons, New York, NY, USA, 3rd edition, 2003.
  16. S. A. Bigler, R. E. Deering, and M. K. Brawer, “Comparison of microscopic vascularity in benign and malignant prostate tissue,” Human Pathology, vol. 24, no. 2, pp. 220–226, 1993. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Weidner, P. R. Carroll, J. Flax, W. Blumenfeld, and J. Folkman, “Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma,” The American Journal of Pathology, vol. 143, no. 2, pp. 401–409, 1993. View at Google Scholar · View at Scopus
  18. O. Melnyk, M. Zimmerman, K. J. Kim, and M. Shuman, “Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model,” The Journal of Urology, vol. 161, no. 3, pp. 960–963, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. W. K. Kelly, S. Halabi, M. A. Carducci et al., “Randomized, double-blind, placebo-controlled phase iii trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401,” Journal of Clinical Oncology, vol. 30, no. 13, pp. 1534–1540, 2012. View at Google Scholar
  20. J. B. Nelson, W. Love, J. L. Chin et al., “Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer,” Cancer, vol. 113, no. 9, pp. 2478–2487, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. K. J. Kim, B. Li, J. Winer et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature, vol. 362, no. 6423, pp. 841–844, 1993. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. C. J. Allegra, G. Yothers, M. J. O'Connell et al., “Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08,” Journal of Clinical Oncology, vol. 29, no. 1, pp. 11–16, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Hung, “Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts,” Molecular Cancer Therapeutics, vol. 6, no. 8, pp. 2149–2157, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. AstraZeneca halts phase III trial of ZIBOTENTAN in non-metastatic castrate resistant prostate cancer, 2011, http://www.astrazeneca.com/Media/Press-releases/Article/0022011AstraZeneca-halts-phase-III-trial-of-ZIBOTENTAN.
  26. R. A. Madan, J. L. Gulley, J. Schlom et al., “Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy,” Clinical Cancer Research, vol. 14, no. 14, pp. 4526–4531, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Bilusic, J. L. Gulley, C. Heery et al., “A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer (CRPC),” ASCO Meeting Abstracts, vol. 29, supplement 7, p. 163, 2011. View at Google Scholar
  28. F. E. Lecouvet, D. Geukens, A. Stainier et al., “Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies,” Journal of Clinical Oncology, vol. 25, no. 22, pp. 3281–3287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Y. Yu, F. E. Nathan, C. S. Higano et al., “Role of detection of metastatic disease as a leading cause of screening failure in an ongoing phase III trial of zibotentan versus placebo in patients with nonmetastatic castration-resistant prostate cancer (CRPC),” ASCO Meeting Abstracts, vol. 29, supplement 7, p. 135, 2011. View at Google Scholar